{"domain":"apollomicsinc.com","status":"valid","tier":"listed","authority":49,"verified":false,"title":"Apollomics Inc.","summary":"The site provides information on Apollomics Inc., a biopharmaceutical company focused on developing oncology therapies. It details their pipeline, including APL-102 (a multi-tyrosine kinase inhibitor), APL-501 (an anti-PD-1 antibody), and Vebreltinib (a c-Met inhibitor). The site also outlines their mission, commitments, leadership, partnerships, and investor relations, emphasizing their goal to advance science and restore lives through innovative cancer treatments.","country":"US","country_source":"ip","publisher_country":null,"publisher_country_source":null,"hosting_country":"US","llms_txt":"https://apollomicsinc.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-23T23:04:34.336Z","agent_terms":null,"categories":["healthcare","science-research"],"capabilities":["mcp"],"inferred_tags":["oncology drugs","biopharmaceutical","apl-102","apl-501","vebreltinib","cancer therapies"],"audience":"mixed","agent_uses":["read_docs","call_api"],"language":"en","platform_generated":false,"agent_summary":"Apollomics Inc.: biopharmaceutical company developing oncology therapies (APL-102, APL-501, vebreltinib), with pipeline, investor info and an MCP endpoint.","llms_txt_cached":"https://agentwebmap.com/v1/domain/apollomicsinc.com/llms.txt","agentic":"interface","section_keys":["ai-agent-access","available-mcp-tools","callwixsiteapi","generatevisitortoken","getbusinessdetails","homepage-link","notes","readfulldocsarticle","readfulldocsmethodschema","searchinsite","searchsiteapidocs","what-visitors-can-do-via-ai-plus-mcp"],"section_partial":false,"section_indexed_at":"2026-10-21T17:18:37.947Z"}